|
1
|
Louis DN, Ohgaki H, Wiestler OD, Cavenee
WK, Ellison DA, Figarella-Branger D, Perry A, Reifenberger G and
von Deimling A: WHO Classification of Tumours of the Central
Nervous System, Revised (4th). 1:IARC. Lyon: 2016.
|
|
2
|
Dolecek TA, Propp JM, Stroup NE and
Kruchko C: CBTRUS statistical report: Primary brain and central
nervous system tumors diagnosed in the United States in 2005–2009.
Neuro Oncol. 14(Suppl 5): v1–v49. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Andersen MH, Svane IM, Becker JC and
Straten PT: The universal character of the tumor-associated antigen
survivin. Clin Cancer Res. 13:5991–5994. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Lens SM, Vader G and Medema RH: The case
for Survivin as mitotic regulator. Curr Opin Cell Biol. 18:616–622.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Aune G, Stunes AK, Tingulstad S, Salvesen
O, Syversen U and Torp SH: The proliferation markers Ki-67/MIB-1,
phosphohistone H3, and survivin may contribute in the
identification of aggressive ovarian carcinomas. Int J Clin Exp
Pathol. 4:444–453. 2011.PubMed/NCBI
|
|
6
|
Chen WB, Cheng XB, Ding W, Wang YJ, Chen
D, Wang JH and Fei RS: Centromere protein F and survivin are
associated with high risk and a poor prognosis in colorectal
gastrointestinal stromal tumours. J Clin Pathol. 64:751–755. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Ekeblad S, Lejonklou MH, Stålberg P and
Skogseid B: Prognostic relevance of survivin in pancreatic
endocrine tumors. World J Surg. 36:1411–1418. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Zhang LQ, Wang J, Jiang F, Xu L, Liu FY
and Yin R: Prognostic value of survivin in patients with non-small
cell lung carcinoma: A systematic review with meta-analysis. PLoS
One. 7:e341002012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Saito T, Arifin MT, Hama S, Kajiwara Y,
Sugiyama K, Yamasaki F, Hidaka T, Arita K and Kurisu K: Survivin
subcellular localization in high-grade astrocytomas: Simultaneous
expression in both nucleus and cytoplasm is negative prognostic
marker. J Neurooncol. 82:193–198. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Xie D, Zeng YX, Wang HJ, Wen JM, Tao Y,
Sham JS and Guan XY: Expression of cytoplasmic and nuclear Survivin
in primary and secondary human glioblastoma. Br J Cancer.
94:108–114. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Shirai K, Suzuki Y, Oka K, Noda SE, Katoh
H, Suzuki Y, Itoh J, Itoh H, Ishiuchi S, Sakurai H, et al: Nuclear
survivin expression predicts poorer prognosis in glioblastoma. J
Neurooncol. 91:353–358. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Jung Y, Joo KM, Seong DH, Choi YL, Kong
DS, Kim Y, Kim MH, Jin J, Suh YL, Seol HJ, et al: Identification of
prognostic biomarkers for glioblastomas using protein expression
profiling. Int J Oncol. 40:1122–1132. 2012.PubMed/NCBI
|
|
13
|
Zhen HN, Zhang X, Hu PZ, Yang TT, Fei Z,
Zhang JN, Fu LA, He XS, Ma FC and Wang XL: Survivin expression and
its relation with proliferation, apoptosis, and angiogenesis in
brain gliomas. Cancer. 104:2775–2783. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Liu X, Chen N, Wang X, He Y, Chen X, Huang
Y, Yin W and Zhou Q: Apoptosis and proliferation markers in
diffusely infiltrating astrocytomas: Profiling of 17 molecules. J
Neuropathol Exp Neurol. 65:905–913. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Habberstad AH, Gulati S and Torp SH:
Evaluation of the proliferation markers Ki-67/MIB-1, mitosin,
survivin, pHH3, and DNA topoisomerase IIα in human anaplastic
astrocytomas-an immunohistochemical study. Diagn Pathol. 6:432011.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Huang Y, Chen X, Chen N, Nie L, Xu M and
Zhou Q: Expression and prognostic significance of survivin splice
variants in diffusely infiltrating astrocytoma. J Clin Pathol.
64:953–959. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Villaamil Medina V, Alvarez García A,
Gallego Aparicio G, Díaz Prado S, López Rivas LA, Caínzos
Santamarina I, Ayerbes Valladares M and Antón Aparicio LM: Tissue
array analysis for the differentiation of gliosis from gliomas. Mol
Med Rep. 4:451–457. 2011.PubMed/NCBI
|
|
18
|
Mellai M, Caldera V, Patrucco A, Annovazzi
L and Schiffer D: Survivin expression in glioblastomas correlates
with proliferation, but not with apoptosis. Anticancer Res.
28:109–118. 2008.PubMed/NCBI
|
|
19
|
Preusser M, Gelpi E, Matej R, Marosi C,
Dieckmann K, Rössler K, Budka H and Hainfellner JA: No prognostic
impact of survivin expression in glioblastoma. Acta Neuropathol.
109:534–538. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Preusser M, Wolfsberger S, Czech T, Slavc
I, Budka H and Hainfellner JA: Survivin expression in intracranial
ependymomas and its correlation with tumor cell proliferation and
patient outcome. Am J Clin Pathol. 124:543–549. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Ridley L, Rahman R, Brundler MA, Ellison
D, Lowe J, Robson K, Prebble E, Luckett I, Gilbertson RJ, Parkes S,
et al: Multifactorial analysis of predictors of outcome in
pediatric intracranial ependymoma. Neuro Oncol. 10:675–689. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Kogiku M, Ohsawa I, Matsumoto K, Sugisaki
Y, Takahashi H, Teramoto A and Ohta S: Prognosis of glioma patients
by combined immunostaining for survivin, Ki-67 and epidermal growth
factor receptor. J Clin Neurosci. 15:1198–1203. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Rousseau A, Kujas M, Bergemer-Fouquet AM,
van Effenterre R and Hauw JJ: Survivin expression in ganglioglioma.
J Neurooncol. 77:153–159. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Uematsu M, Ohsawa I, Aokage T, Nishimaki
K, Matsumoto K, Takahashi H, Asoh S, Teramoto A and Ohta S:
Prognostic significance of the immunohistochemical index of
survivin in glioma: A comparative study with the MIB-1 index. J
Neurooncol. 72:231–238. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Lin H, Wang Y, Zhang X, Liu B, Zhang W and
Cheng J: Prognostic significance of kappaB-Ras1 expression in
gliomas. Med Oncol. 29:1272–1279. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Okada H, Low KL, Kohanbash G, McDonald HA,
Hamilton RL and Pollack IF: Expression of glioma-associated
antigens in pediatric brain stem and non-brain stem gliomas. J
Neurooncol. 88:245–250. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Yeung JT, Hamilton RL, Okada H, Jakacki RI
and Pollack IF: Increased expression of tumor-associated antigens
in pediatric and adult ependymomas: Implication for vaccine
therapy. J Neurooncol. 111:103–111. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Skjulsvik AJ, Mørk JN, Torp MO and Torp
SH: Ki-67/MIB-1 immunostaining in a cohort of human gliomas. Int J
Clin Exp Pathol. 7:8905–8910. 2014.PubMed/NCBI
|
|
29
|
Prayson RA: The utility of MIB-1/Ki-67
immunostaining in the evaluation of central nervous system
neoplasms. Adv Anat Pathol. 12:144–148. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Johannessen AL and Torp SH: The clinical
value of Ki-67/MIB-1 labeling index in human astrocytomas. Pathol
Oncol Res. 12:143–147. 2006. View Article : Google Scholar : PubMed/NCBI
|
